Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1365-1377

  Field, Katherine M ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Brackenridge Hospital   (United States)

^c BCPS   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; C reactive protein; CRP; HMG CoA reductase inhibitor; LDL; Low density lipoprotein cholesterol; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ASSAY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG INDICATION; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; REVIEW; RISK FACTOR; RISK REDUCTION; STANDARDIZATION; STROKE;

ANIMALS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; METABOLIC SYNDROME X; PRAVASTATIN; PYRROLES; RISK FACTORS; SIMVASTATIN;

EID: 26044461187     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1365     Document Type: Review

References (49)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association, 2002.
2. Breslow JL. Cardiovascular disease burden increases, NIH funding decreases. Nat Med 1997;3:600-1.
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: the global burden of disease study. Lancet 1997;349:1269-76.
4. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
5. Keys A. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
6. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the millennium, triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
7. Ridker PM. Highly sensitive CRP and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92(suppl):17K-22.
8. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
9. Stary HC, Chandler AB, Glagor S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1994;89:2462-78.
10. Libby P, Ridker PM. Inflammation and atherosclerosis: the role of C-reactive protein in risk assessment. Am J Med 2004;116(6A):9s-16.
11. Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease, Vol. 2. Philadelphia, PA: Lippincott-Raven, 1996:492-510.
12. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932-40.
13. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003;92(suppl 1):10i-18.
14. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-43.
15. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107: 499-511.
16. Mosca L. C-reactive protein: to screen or not to screen? N Engl J Med 2002;347:1615-17.
17. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins and serum amyloid A protein. Adv Immunol 1983;34:141-212.
18. Munford RS. Statins and the acute phase response. N Engl J Med 2001;344:2016-18.
19. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
20. Suleiman M, Aronson D, Reisner SA, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 2003;115:695-701.
21. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
22. Lloyd-Jones DM, Levy D. C-reactive protein in the prediction of cardiovascular events [letter]. N Engl J Med 2003;348:1059.
23. Brezis M. C-reactive protein in the prediction of cardiovascular events [letter]. N Engl J Med 2003;348:1059.
24. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation 2003;108:161-5.
25. Lowe G, Upton M, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional survey. Thromb Haemost 2001;86:550-6.
26. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-53.
27. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and the risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-7.
28. Blake GJ, Rifai N, Buring J, Ridker PM. Blood pressure, C-reactive protein, and the risk of future cardiovascular events. Circulation 2003;108:2993-9.
29. Van der Meer IM, de Maat MPM, Kiliaan AJ, van der Kuip DAM, Hofman A, Witteman JCM. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam study. Arch Intern Med 2003;163:1323-8.
30. Chan KY, Boucher ES, Gandhi PJ, Silva MA. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health-Syst Pharm 2004;61:1676-81.
31. Nissen SE, Tuzcu EM, Schoenhagen P, et al, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291(9):1071-80.
32. Cannon CP, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504.
33. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670-82.
34. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286(1):64-70.
35. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days, an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52.
36. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794-9.
37. Lee IT, Sheu WH, Lin SY, Lee WJ, Song YM, Liu HC. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabetes Complications 2002;16:382-5.
38. Van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C, for the DALI Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003;166:129-35.
39. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18.
40. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-6.
41. Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
42. Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
43. Ridker PM, Rifai N, Clearfield M, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
44. Nissen SE, Tuzcu EM, Schoenhagen P, et al, for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352(I):29-38.
45. Ridker PM, Cannon CP, Morrow D, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20-8.
46. Ridker PM, for the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-7.
47. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
48. Yeh ETH, Willerson JT. Coming of age of C-reactive protein: using inflammatory markers in cardiology. Circulation 2003;107:370-2.
49. Mitka M. Panel endorses limited role for CRP tests. JAMA 2003;289(8):973-4.